Publications by authors named "Steven A Gilbert"

Claim this Profile
E
Efficacy and Safety of Zimlovisertib, Ritlecitinib, and Tofacitinib, Alone and in Combination, in Patients With Moderate to Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate.
Spencer I Danto, Mikhail Salganik, Anindita Banerjee, Pawel Hrycaj, Irina Jashi, Steven A Gilbert

Arthritis Rheumatol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Trial: Study to Investigate the Efficacy and Safety of the Alpha-2-Delta Ligand PD-217,014 in Patients With Irritable Bowel Syndrome.
Lesley A Houghton, Simiao Gao, Steven A Gilbert, Benoit Coffin, Magnus Simren

Aliment Pharmacol Ther· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exploratory pharmacodynamics and efficacy of PF-06817024 in a Phase 1 study of patients with chronic rhinosinusitis and atopic dermatitis.
Spencer I Danto, Nikolaos Tsamandouras, Padma Reddy, Steven A Gilbert, Jessica Y Mancuso

Allergy Asthma Clin Immunol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predicting Treatment Responses in Patients With Osteoarthritis: Results From Two Phase III Tanezumab Randomized Clinical Trials.
Luana Colloca, Robert H Dworkin, John T Farrar, Leslie Tive, Jiyue Yang, Steven A Gilbert

Clin Pharmacol Ther· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Interleukin-1 Receptor-Associated Kinase 4 Inhibitor PF-06650833 Blocks Inflammation in Preclinical Models of Rheumatic Disease and in Humans Enrolled in a Randomized Clinical Trial.
Aaron Winkler, Weiyong Sun, Saurav De, Aiping Jiao, M Nusrat Sharif, Steven A Gilbert

Arthritis Rheumatol· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Historical Benchmarks for Quality Tolerance Limits Parameters in Clinical Trials.
Marcin Makowski, Ruma Bhagat, Soazig Chevalier, Steven A Gilbert, Dagmar R Görtz

Ther Innov Regul Sci· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TYK2/JAK1 Inhibitor PF-06700841 in Patients with Plaque Psoriasis: Phase IIa, Randomized, Double-Blind, Placebo-Controlled Trial.
Seth B Forman, David M Pariser, Yves Poulin, Michael S Vincent, Steven A Gilbert

J Invest Dermatol· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, tolerability, pharmacokinetics, and pharmacodynamics of PF-06650833, a selective interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor, in single and multiple ascending dose randomized phase 1 studies in healthy subjects.
Spencer I Danto, Negin Shojaee, Ravi Shankar P Singh, Cheryl Li, Steven A Gilbert

Arthritis Res Ther· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study.
Jan Astermark, Sharyne M Donfield, Donna M DiMichele, Alessandro Gringeri, Steven A Gilbert

Blood· January 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Competition between Native Populus deltoides and Invasive Tamarix ramosissima and the Implications for Reestablishing Flooding Disturbance.
Anna A Sher, Diane L Marshall, Steven A Gilbert

Conserv Biol· December 2000

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis